LONDON, ZUG, 17 March 2026. Sanius Health Limited (“Sanius”) is an AI-native care management and life sciences platform, delivering global research, evidence generation and data capabilities. Today, the company announced the acquisition of Switzerland-based Kielo Research GmbH (“Kielo”), a specialist patient-centred research organisation headquartered in Zug, Switzerland. The acquisition strengthens Sanius Health’s capabilities in integrating patient perspectives into the development of medicines, medical technologies and healthcare services. It also expands the platform’s expertise across a broad set of therapeutic areas, including cardiovascular disease, oncology, respiratory medicine, metabolic disease, neurology, dermatology and vaccine development.

Kielo Research is recognised for its deep expertise in patient preference studies, patient-reported outcomes and qualitative research that captures how patients experience diseases and treatments. These insights enable healthcare organisations to design more effective therapies, clinical trials and care pathways by ensuring patient perspectives are meaningfully incorporated throughout the development process.

By combining Kielo’s expertise in patient-centred research with Sanius Health’s secure research infrastructure, advanced analytics and patient engagement capabilities, the organisations will expand their ability to generate high-quality evidence that reflects real patient experiences and priorities.

Sanius Health operates across the United States, the United Kingdom and Asia, working with healthcare providers, patients, researchers and life sciences companies to support better care and the development of treatments through the responsible use of health insights, clinical expertise and advanced analytics. By connecting hospital care pathways, genomic research and long-term disease management programmes, Sanius Health helps improve patient outcomes, reduce avoidable hospital visits and support the development and delivery of innovative therapies.

The integration of Kielo Research will further strengthen Sanius Health’s ability to translate patient insights into meaningful evidence that informs the development of safer and more effective treatments.

Together, Sanius Health and Kielo Research will support partners in bringing the patient voice into decision-making across the full development lifecycle, from early product design and clinical trials to regulatory engagement and real-world evidence generation. Sanius CEO and Founder Orlando Agrippa commented:

“Welcoming Kielo Research into Sanius marks an exciting step forward in our mission to ensure that patient experiences and perspectives help shape the future of healthcare innovation. By combining our capabilities, we can support life sciences organisations with insights that reflect what truly matters to patients while maintaining the highest standards of trust and responsible research.

Our patient working group and clinical advisory board are particularly excited about this as we accelerate more patient preference studies, patient support programmes, Delphi panels, and research designed to improve outcomes for patients.”

Kielo Chief Scientist & Founder Tommi Tervonen added, “We are delighted to join Sanius Health. Both organisations share a strong commitment to ensuring that the patient voice is heard and reflected in the development of new treatments and healthcare solutions. By combining Kielo’s expertise in patient-centred research with Sanius Health’s technology and global research capabilities, we will generate deeper insights into patient experiences and preferences. This will help ensure that therapies, clinical trials and care pathways are designed with the needs and priorities of patients at the centre.”

For further information, please contact the Sanius press office: press@saniushealth.com or hello@saniushealth.com 

‍

About Sanius Health 

Sanius Health is a leading real-world evidence and patient-generated data company focused on rare and underserved conditions, developing research, evidence and data solutions for healthcare and life sciences organisations. The platform brings together hospital pathways, genomic insights and longitudinal disease management to support advanced therapies, care coordination and real-world clinical insight.

Through its rare disease and oncology registries, Sanius Health supports clinical trial recruitment, regulatory validation and reimbursement pathways, connecting healthcare providers, researchers and life sciences organisations through established research partnerships.

Combined with integration across one of the largest primary care provider footprints in the United Kingdom, the platform supports patient management, care delivery, pathway redesign, cost improvement and accelerated clinical trials, while generating decision-grade evidence for regulators, payers and life sciences partners.

The platform holds particular strength in rare diseases and haematology, with programmes across sickle cell disease (SCD), myeloproliferative neoplasms (MPNs), multiple myeloma (MM), Waldenström’s macroglobulinaemia (WM), chronic myeloid leukaemia (CML) and chronic lymphocytic leukaemia (CLL).

‍

About Kielo Research

Kielo Research is a specialist health economics and patient preference research company, focused on integrating the patient perspective into the development and evaluation of medicines, medical technologies and healthcare services. The company supports pharmaceutical, biotechnology and medical device organisations with advanced research methodologies that capture how patients value treatment outcomes, risks and quality-of-life impacts.

Through qualitative and quantitative studies involving patients, caregivers and healthcare professionals, Kielo generates evidence used in clinical development, regulatory submissions and health technology assessments. The firm’s scientific team includes internationally recognised experts in patient preference research and patient-reported outcomes, with a strong track record of peer-reviewed publications and global life sciences collaborations.

Kielo has conducted studies across a range of therapeutic areas, including cardiovascular disease, oncology, respiratory medicine, metabolic disorders, neurology, dermatology and vaccines, helping healthcare innovators design treatments that better reflect patient priorities and real-world needs.